These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33664086)

  • 1. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
    Madan RA; Karzai F; Donahue RN; Al-Harthy M; Bilusic M; Rosner II; Singh H; Arlen PM; Theoret MR; Marté JL; Cordes L; Couvillon A; Hankin A; Williams M; Owens H; Lochrin SE; Chau CH; Steinberg S; Figg WD; Dahut W; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33664086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
    Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
    Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
    De Giorgi U; Hussain M; Shore N; Fizazi K; Tombal B; Penson D; Saad F; Efstathiou E; Madziarska K; Steinberg J; Sugg J; Lin X; Shen Q; Sternberg CN
    Eur J Cancer; 2021 Dec; 159():237-246. PubMed ID: 34784577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
    Soleimani M; Zou K; Sunderland K; Struss W; Eigl BJ; Nappi L; Kollmannsberger CK; Finch D; Noonan K; Vergidis J; Zulfiqar M; Chi KN; Khalaf DJ
    Eur J Cancer; 2021 Jul; 152():215-222. PubMed ID: 34130153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
    Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
    N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
    Nagahara A; Uemura M; Sato M; Nakata W; Tsujihata M; Takao T; Matsumura S; Nishimura K; Takada S; Iwanishi T; Kobayashi Y; Ishizuya Y; Takada T; Okada K; Inoue H; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N
    Jpn J Clin Oncol; 2024 May; 54(5):584-591. PubMed ID: 38305451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study.
    Pu YS; Ahn H; Han W; Huang SP; Wu HC; Ma L; Yamada S; Suga K; Xie LP
    Adv Ther; 2022 Jun; 39(6):2641-2656. PubMed ID: 35397772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
    Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
    Aggarwal RR; Schweizer MT; Nanus DM; Pantuck AJ; Heath EI; Campeau E; Attwell S; Norek K; Snyder M; Bauman L; Lakhotia S; Feng FY; Small EJ; Abida W; Alumkal JJ
    Clin Cancer Res; 2020 Oct; 26(20):5338-5347. PubMed ID: 32694156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
    Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
    Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.
    Attard G; Borre M; Gurney H; Loriot Y; Andresen-Daniil C; Kalleda R; Pham T; Taplin ME;
    J Clin Oncol; 2018 Sep; 36(25):2639-2646. PubMed ID: 30028657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients.
    Kim CS; Theeuwes A; Kwon DD; Choi YD; Chung BH; Lee HM; Lee KH; Lee SE
    Investig Clin Urol; 2016 May; 57(3):174-83. PubMed ID: 27195316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
    Tsuzuki S; Nakanishi S; Tamaki M; Oshiro T; Miki J; Yamada H; Shimomura T; Kimura T; Furuta N; Saito S; Egawa S
    PLoS One; 2021; 16(10):e0258160. PubMed ID: 34597353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
    Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
    Bryce AH; Alumkal JJ; Armstrong A; Higano CS; Iversen P; Sternberg CN; Rathkopf D; Loriot Y; de Bono J; Tombal B; Abhyankar S; Lin P; Krivoshik A; Phung D; Beer TM
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):221-227. PubMed ID: 28117385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.